RT-310 not checked

Resurge Therapeutics Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
3 active
3 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)”In the company’s words, NCT07928206 on ClinicalTrials.gov
Tested for
BPH (Benign Prostatic Hyperplasia) (2 trials), Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms
Main trialPhase 2
“A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of RT-310 (Paclitaxel) Protate Implant(s) for Treatment of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)”In the company’s words, NCT07928206 on ClinicalTrials.gov

Other drugs for BPH (Benign Prostatic Hyperplasia)

All 9 drugs for BPH (Benign Prostatic Hyperplasia)

Coming up1

Changes1

Last 90 days

Trials3

TrialPhaseCompletesWhat it tests
Phase 2Not yet recruiting Dec 2028 RELEASE Ph2 RT-310 BPH Study
Phase 1/2Active, not recruiting 26 Feb 2026 RT-310 Safety and Feasibility BPH Study
Phase 1Active, not recruiting 6 May 2025 RT-310 Dose Escalation BPH Study
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow RT-310

Following is part of Solo: you see every change to RT-310 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in